First‐in‐human study with SAR445088: A novel selective classical complement pathway inhibitor

SAR445088 is an anti‐C1s humanized monoclonal antibody that inhibits activated C1s in the proximal portion of the classical complement system and has the potential to provide clinical benefit in the treatment of complement‐mediated diseases. A phase I, first‐in‐human, double‐blind, randomized, place...

Descripción completa

Detalles Bibliográficos
Autores principales: Chow, Timothy, Shamszad, Pirouz, Vinnard, Christopher, Yoon, Esther, Belinski, Julia, Karpenko, Irene, Perrin, Laurent, Auwarter, Kristen, Storek, Michael, Surks, Howard, Wong, Nancy, Cohen, Yehuda Z.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087070/
https://www.ncbi.nlm.nih.gov/pubmed/36661084
http://dx.doi.org/10.1111/cts.13481

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087070/
https://www.ncbi.nlm.nih.gov/pubmed/36661084
http://dx.doi.org/10.1111/cts.13481

Ejemplares similares